Nuvalent, Inc. (NUVL) |
|
45.63 3.55 (8.44%)
|
09-27 16:00 |
|
Open: |
43.85 |
Pre. Close: |
42.08 |
|
High:
|
45.89 |
Low:
|
43.74 |
|
Volume:
|
438,520 |
Market Cap:
|
2,602(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 4:21:08 PM |
|
Short-term rate:
|
  |
| Stoxline posted a STRONG BUY today, upgraded from lower rating. Upward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 57.97 One year: 67.72 |
| Support: |
Support1: 43.59 Support2: 39.86 |
| Resistance: |
Resistance1: 49.63 Resistance2: 57.97 |
| Pivot: |
45.37  |
| Moving Average: |
MA(5): 43.4 MA(20): 45.73
MA(100): 43.25 MA(250): 34.71 |
| MACD: |
MACD(12,26): -0.4 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 36.3 %D(3): 32.9 |
| RSI: |
RSI(14): 53.5 |
| 52-week: |
High: 50.58 Low: 17.75 |
| Average Vol(K): |
3-Month: 347 (K) 10-Days: 648 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NUVL ] has closed below upper band by 47.1%. Bollinger Bands are 31.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
45.91 - 46.14 |
46.14 - 46.37 |
|
Low:
|
43.22 - 43.45 |
43.45 - 43.68 |
|
Close:
|
45.25 - 45.62 |
45.62 - 46 |
|
Company Description |
|
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Wed, 27 Sep 2023
Stifel Initiates Coverage on Nuvalent Inc with Positive Outlook - Best Stocks
Wed, 27 Sep 2023
Challenging Road Ahead for Cancer Drugs, Nuvalent Seeks to ... - Investing.com UK
Wed, 27 Sep 2023
Is Nuvalent Inc (NUVL) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
Mon, 18 Sep 2023
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 ... - BioSpace
Tue, 12 Sep 2023
Fairmount Funds Management LLC Grows Stock Holdings in ... - MarketBeat
Thu, 07 Sep 2023
Wellington Management Group LLP Increases Stake in Nuvalent ... - Best Stocks
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
52 (M) |
| Shares Float |
23 (M) |
|
% Held by Insiders
|
4.4 (%) |
|
% Held by Institutions
|
106.7 (%) |
|
Shares Short
|
4,470 (K) |
|
Shares Short P.Month
|
4,490 (K) |
Stock Financials |
|
EPS
|
-1.83 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
7.38 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-20.3 |
|
Return on Equity (ttm)
|
-29.8 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-83 (M) |
|
Levered Free Cash Flow
|
-47 (M) |
Stock Valuations |
|
PE Ratio
|
-25.08 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
6.17 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-28.54 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
